{"id":{"repo_id":"utswmed","oai_identifier":"oai:utswmed-ir.tdl.org:2152.5/10628"},"canonical_url":"https://search.dev.ndltd.org/etd/utswmed/oai:utswmed-ir.tdl.org:2152.5/10628","repository":{"repo_id":"utswmed","name":"University of Texas Southwestern Medical Center","base_url":"https://utswmed-ir.tdl.org/server/oai/request"},"display":{"title":"The Potential of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in Cancer Cachexia","abstract":"The general metadata -- e.g., title, author, abstract, subject headings, etc. -- is publicly available, but access to the submitted files is restricted to UT Southwestern campus access and/or authorized UT Southwestern users.","abstract_html":"The general metadata -- e.g., title, author, abstract, subject headings, etc. -- is publicly available, but access to the submitted files is restricted to UT Southwestern campus access and/or authorized UT Southwestern users.","abstract_has_math":false,"creators":["Olaechea, Santiago"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Infante, Rodney Elwood","Iyengar, Puneeth","Gilmore, L. Anne"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-06-03T19:58:34Z","date_published":"2025-06-03T19:58:34Z","updated_at":"2026-07-24T05:52:29Z","subjects":["Anti-Inflammatory Agents, Non-Steroidal","Body Weight","Cachexia","Neoplasms","Weight Loss"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["1522121971"],"render_values":[{"text":"1522121971","href":null,"code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2152.5/10628","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Infante, Rodney Elwood","Iyengar, Puneeth","Gilmore, L. Anne"]},{"key":"dc:creator","label":"Author","values":["Olaechea, Santiago"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025-06-03T19:58:34Z","2023-05","May 2023"]},{"key":"dc:type","label":"Dc Type","values":["Thesis","text"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Anti-Inflammatory Agents, Non-Steroidal","Body Weight","Cachexia","Neoplasms","Weight Loss"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://hdl.handle.net/2152.5/10628","1522121971"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The general metadata -- e.g., title, author, abstract, subject headings, etc. -- is publicly available, but access to the submitted files is restricted to UT Southwestern campus access and/or authorized UT Southwestern users.","BACKGROUND: Cachexia is an inflammatory and metabolic syndrome of unintentional weight loss through depletion of muscle and adipose tissue. Despite extensive involvement of prostaglandin signaling in central and peripheral signaling pathways implicated in the development of cachexia, there is limited clinical knowledge of how chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) might affect cachexia presentation. OBJECTIVE: The purpose of this study was to investigate associations between prior long-term use of NSAIDs with cachexia incidence and post-diagnosis weight loss progression in a retrospective cancer patient cohort. METHODS: Of 3,802 lung or gastrointestinal cancer patient records, 3,180 comprised our final cohort. Patient demographic information, tumor qualities, medication histories, and comorbidities were assessed. Cachexia was defined as having developed prior to oncologic treatment. Statistical evaluations included categorical, multivariate logistic regression, and log-rank survival analyses. Development of substantial post-diagnosis weight loss was calculated and interpreted for patients who did not meet criteria for cachectic weight loss at diagnosis. RESULTS: Chronic prior use of any NSAID was associated with approximate absolute and relative reductions in cachexia incidence at diagnosis of 10 and 35 percent (P<0.0001). In multivariate analyses, patients with prior NSAID medication use demonstrated a 23 percent reduction in likelihood of cachexia incidence (odds ratio=0.750; 95% CI=0.580, 0.969; P=0.280). Patients without cachexia at diagnosis were significantly more likely to develop substantial post-diagnosis weight loss if they had chronic pre-diagnosis NSAID use (OR=1.411; 95% CI=1.082, 1.840; P=0.011). CONCLUSIONS: The findings of this study suggest a protective effect of prior NSAID use against manifestations of the cachexia phenotype at cancer diagnosis. The clinical outcomes we observed are consistent with the biomolecular reasoning that cachexia progression would possess vulnerability to this medication type, which specifically mitigates inflammatory mechanisms of the syndrome not attributable to the body tissue wasting observed consequently to oncologic therapies. These observations support further exploration of potential therapeutic benefits from this medication class early in cancer management."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["The Potential of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in Cancer Cachexia"]}]}],"canonical_facts":{"dc:contributor":["Infante, Rodney Elwood","Iyengar, Puneeth","Gilmore, L. Anne"],"dc:creator":["Olaechea, Santiago"],"dc:date":["2025-06-03T19:58:34Z","2023-05","May 2023"],"dc:description":["The general metadata -- e.g., title, author, abstract, subject headings, etc. -- is publicly available, but access to the submitted files is restricted to UT Southwestern campus access and/or authorized UT Southwestern users.","BACKGROUND: Cachexia is an inflammatory and metabolic syndrome of unintentional weight loss through depletion of muscle and adipose tissue. Despite extensive involvement of prostaglandin signaling in central and peripheral signaling pathways implicated in the development of cachexia, there is limited clinical knowledge of how chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) might affect cachexia presentation. OBJECTIVE: The purpose of this study was to investigate associations between prior long-term use of NSAIDs with cachexia incidence and post-diagnosis weight loss progression in a retrospective cancer patient cohort. METHODS: Of 3,802 lung or gastrointestinal cancer patient records, 3,180 comprised our final cohort. Patient demographic information, tumor qualities, medication histories, and comorbidities were assessed. Cachexia was defined as having developed prior to oncologic treatment. Statistical evaluations included categorical, multivariate logistic regression, and log-rank survival analyses. Development of substantial post-diagnosis weight loss was calculated and interpreted for patients who did not meet criteria for cachectic weight loss at diagnosis. RESULTS: Chronic prior use of any NSAID was associated with approximate absolute and relative reductions in cachexia incidence at diagnosis of 10 and 35 percent (P<0.0001). In multivariate analyses, patients with prior NSAID medication use demonstrated a 23 percent reduction in likelihood of cachexia incidence (odds ratio=0.750; 95% CI=0.580, 0.969; P=0.280). Patients without cachexia at diagnosis were significantly more likely to develop substantial post-diagnosis weight loss if they had chronic pre-diagnosis NSAID use (OR=1.411; 95% CI=1.082, 1.840; P=0.011). CONCLUSIONS: The findings of this study suggest a protective effect of prior NSAID use against manifestations of the cachexia phenotype at cancer diagnosis. The clinical outcomes we observed are consistent with the biomolecular reasoning that cachexia progression would possess vulnerability to this medication type, which specifically mitigates inflammatory mechanisms of the syndrome not attributable to the body tissue wasting observed consequently to oncologic therapies. These observations support further exploration of potential therapeutic benefits from this medication class early in cancer management."],"dc:format":["application/pdf"],"dc:identifier":["https://hdl.handle.net/2152.5/10628","1522121971"],"dc:language":["en"],"dc:subject":["Anti-Inflammatory Agents, Non-Steroidal","Body Weight","Cachexia","Neoplasms","Weight Loss"],"dc:title":["The Potential of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in Cancer Cachexia"],"dc:type":["Thesis","text"]},"updated_at":"2026-07-24T05:52:29Z"}